Archive
All News
Every briefing, headline, and filing we've published, newest first.
Money
Avalyn Pharma plans a $182M IPO to fund late‑stage trials for inhaled pirfenidone and nintedanib, signaling in…
![<![CDATA[Contributor: Prior Authorization in 2026—CMS Is Rebuilding the Operating Model]]>](https://images.builtfor.ai/images/article-images/cdata-contributor-prior-authorization-in-2026-cms-is-rebuild.png)
PolicySTAT News ↗
A Utah pilot to renew prescriptions using a bot faced backlash from the state's medical board, which called fo…
PipelineEndpoints News ↗
Novartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, des…
MoneyBioPharma Dive ↗
Lilly shares dipped, and Novo’s climbed, as Foundayo’s early trajectory diverged from that of oral…
NegotiationsDrug Channels ↗
Today’s guest post comes from Laura Jensen, Chief Commercial Officer and President, Pharma Direct at GoodRx. L…
PipelineSTAT News ↗
This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more …
MoneyBioPharma Dive ↗
The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume …
PeopleSTAT News ↗
A gene therapy for deafness, all eyes on Erasca, and other biotech news from The Readout…
DealsEndpoints News ↗
Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals t…
PolicyPharmaVoice ↗
Debate about drug costs erupted among prominent healthcare figures, including Dr. Oz, Mark Cuban, Calley Means…
PolicyDrug Channels ↗
By Bryce Platt, PharmD Minnesota’s new 340B data reveal a growing disconnect between the program’s size and th…
PipelineFiercePharma ↗
The once-daily HIV treatment regimen offers a new mechanism of action in the HIV treatment market.…
PipelineFierceBiotech ↗
Kyverna Therapeutics has unveiled the full results from its registrational trial of miv-cel in stiff person sy…
Pipeline
Roche’s Enspryng cut MOGAD relapse risk by 68%, a pivotal step toward the first FDA-approved therapy for the d…
PipelineBioPharma Dive ↗
A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private c…
PipelineSTAT News ↗
Flu shot no longer mandated for U.S. troops, "healthy" snacks, and other news from Morning Rounds…
PipelineFierceBiotech ↗
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, R…
PipelineFiercePharma ↗
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blo…
DealsBriefing
UCB’s $650 million deal for Neurona Therapeutics signals a move to blend neurology heritage with next‑gen cell…
The WeekPharmaceutical Technology ↗
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicin…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.